Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nintedanib Esylate

FDA-approved product (capsule, oral), marketed as Nintedanib Esylate, Ofev.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Nintedanib Esylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Idiopathic pulmonary fibrosis
  • Interstitial pneumonitis
  • Non-small cell lung carcinoma
  • Systemic scleroderma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nintedanib Esylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nintedanib Esylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer

    NCT02182219 · start 2005-11-01

    Registered record
    Registry ID
    NCT02182219
    Conditions
    Prostatic Neoplasms
    Interventions
    BIBF 1120
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-11-01
    Completion
    Not recorded
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    InterventionBIBF 1120
    PhasePhase 1
    Registry statusCompleted

  • Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies

    NCT02182245 · start 2005-10-01

    Registered record
    Registry ID
    NCT02182245
    Conditions
    Genital Neoplasms, Female
    Interventions
    BIBF 1120; Paclitaxel; Carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-10-01
    Completion
    Not recorded
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGenital Neoplasms, Female
    InterventionBIBF 1120; Paclitaxel; Carboplatin
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics/Bioavailability of BIBF 1120 Administered to Healthy Male Volunteers

    NCT02182076 · start 2005-10

    Registered record
    Registry ID
    NCT02182076
    Conditions
    Healthy
    Interventions
    BIBF 1120
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-10
    Completion
    Not recorded
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBIBF 1120
    PhasePhase 1
    Registry statusCompleted

  • To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

    NCT01951846 · start 2002-11

    Registered record
    Registry ID
    NCT01951846
    Conditions
    Malignant Solid Tumour
    Interventions
    BIBF 1120
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-11
    Completion
    Not recorded
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Solid Tumour
    InterventionBIBF 1120
    PhasePhase 1
    Registry statusCompleted

  • Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis

    NCT02230982

    Registered record
    Registry ID
    NCT02230982
    Conditions
    Idiopathic Pulmonary Fibrosis
    Interventions
    nintedanib
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis
    Interventionnintedanib
    PhaseNot recorded
    Registry statusNo longer available